Compare KW & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KW | VIR |
|---|---|---|
| Founded | 1977 | 2016 |
| Country | United States | United States |
| Employees | N/A | 367 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2007 | 2019 |
| Metric | KW | VIR |
|---|---|---|
| Price | $11.00 | $8.54 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $11.00 | ★ $19.43 |
| AVG Volume (30 Days) | 740.2K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.41% | N/A |
| EPS Growth | ★ 50.00 | 17.49 |
| EPS | ★ 0.10 | N/A |
| Revenue | $62,633,000.00 | ★ $68,556,000.00 |
| Revenue This Year | $81.79 | $270.22 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $110.30 | ★ N/A |
| Revenue Growth | ★ 23.94 | N/A |
| 52 Week Low | $5.98 | $4.16 |
| 52 Week High | $11.09 | $11.66 |
| Indicator | KW | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 59.87 | 35.05 |
| Support Level | $10.82 | $8.47 |
| Resistance Level | $11.09 | $10.29 |
| Average True Range (ATR) | 0.03 | 0.41 |
| MACD | 0.00 | -0.18 |
| Stochastic Oscillator | 60.47 | 0.26 |
Kennedy-Wilson Holdings Inc is a real estate investment company that owns, operates, and invests in real estate both on its own and through its investment management platform. The Company focuses on multifamily and office properties, as well as industrial and debt investments. It has two business segments; the Consolidated Portfolio includes investment activities that involve ownership of multifamily units, office, retail and industrial space, and one hotel, and The Co-Investment Portfolio segment consists of investments the Company makes with partners in which it receives fees, performance allocations that it earns on its fee-bearing capital and distributions and profits from its ownership interest in the underlying operations of its co-investments.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.